# An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

> **NCT01855074** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Schizophrenia
- Schizophreniform Disorder
- Schizoaffective Disorder

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01855074
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855074, "An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01855074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*